Share

June 2016; 6 (3) ResearchOpen Access

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Patient management considerations

Robert J. Fox, Andrew Chan, Ralf Gold, J. Theodore Phillips, Krzysztof Selmaj, Ih Chang, Mark Novas, Jitesh Rana, Jing L. Marantz
First published April 1, 2016, DOI: https://doi.org/10.1212/CPJ.0000000000000238
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
5006

Share

Article Information

vol. 6 no. 3 220-229
DOI: 
https://doi.org/10.1212/CPJ.0000000000000238
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received August 28, 2015
  • Accepted November 30, 2015
  • First Published April 1, 2016.

Article Versions

Copyright & Usage: 
© 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Robert J. Fox, MD,
    2. Andrew Chan, MD,
    3. Ralf Gold, MD,
    4. J. Theodore Phillips, MD, PhD,
    5. Krzysztof Selmaj, MD, PhD,
    6. Ih Chang, PhD,
    7. Mark Novas, MD,
    8. Jitesh Rana, MD and
    9. Jing L. Marantz, MD, PhD
  1. Robert J. Fox, MD,
    2. Scientific Advisory Boards:

    1. Biogen Idec, Novartis

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial Board, Neurology Editorial Board, Multiple Sclerosis Journal

    Patents:

    1. NONE

    Publishing Royalties:

    1. Multiple Sclerosis and Related Disorders, Demos Medical, 2013

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Actelion, Biogen Idec, MedDay, Novartis, Mallinckrodt, Teva, and XenoPort

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research grant from Novartis.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National MS Society, RC 1004-A-5, 2010- 2013; RG 4778-A-6, 2013-2018; NIH 1U01NS082329-01A1, 2013- 2018; Consortium of MS Centers

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Andrew Chan, MD,
    3. Scientific Advisory Boards:

    1. Served on scientific advisory boards for (1) Bayer, (2) Biogen (3) Genzyme, (4) Novartis Pharma, (5) UCB

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Bayer, speaker honoraria, (2) Biogen, speaker honoraria, (3) Genzyme, speaker honoraria, (4) Merck, speaker honoraria, (5) Novartis Pharma, speaker honoraria (6) Teva Neuroscience, speaker honoraria, (7) Roche, speaker honoraria (7) Almirall Hermal GmbH (8) Sanofi Aventis

    Editorial Boards:

    1. (1) International Journal of Endocrinology, Guest editor, 2012

    Patents:

    1. Proteomic profile of NMO

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Bayer, consultant, (2) Biogen, consultant, (3) Genzyme, consultant (4) Merck, consultant, (5) Novartis, consultant, (6) UCB, consultant

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biogen, (2) Novartis Pharma, (3) Genzyme, (4) Bayer Schering, (5) Merck Serono

    Research Support, Government Entities:

    1. (1) German Ministry for Education and Research (BMBF, ?German Competence Network Multiple Sclerosis? (KKNMS), CONTROL MS), 01GI0914, 2009-2014

    Research Support, Academic Entities:

    1. Ruhr University Bochum, Research support (FoRUM)

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. (1) Sanofi-Aventis, 2010-2011, expert consultant, authoring of a clinical overview that was submitted to german regulatory authorities for approval of methylprednisolone in the treatment of Multiple Sclerosis

  3. Ralf Gold, MD,
    4. Scientific Advisory Boards:

    1. (1) TEVA three DSMB boards (2) BiogenIdec advisory boards (3) BayerSchering advisory boards (4) Novartis advisory boards

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) speaker at BiogenIdec symposia and satellites (2) speaker at TEVA symposia and satellites (3) speaker at BayerSchering symposia and satellites (4) speaker at Novartis symposia and satellites (5) Merck Serono

    Editorial Boards:

    1. (1) Therapeutic Advances in Neurological Diseases, editor since 2008 (2) Am J Path, editorial board 2009-2012 (3) J Neuroimmunol, editorial board since 2006 (4) Exp Neurol Editorial board since 2013

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. for BiogenIdec, ELAN, TEVA several times once for Chugai Inc.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) TEVA (2) BiogenIdec (3) BayerSchering (4) MerckSerono (5) Novartis

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. J. Theodore Phillips, MD, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1. Acorda, speaker honoraria 2. Biogen-Idec, speaker honoraria 3. Genzyme, speaker honoraria 4. Sanofi, speaker honoraria 5. Serono, advisory board honorarium

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. 1. Acorda 2. Biogen-Idec 3. Genzyme 4. Sanofi

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1. Biogen Idec 2. Roche

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Krzysztof Selmaj, MD, PhD,
    6. Scientific Advisory Boards:

    1. Genzyme,BiogenIdec,Novartis,Synthon, Roche, Receptos, TEVA

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker for Biogen Idec, Novartis, TEVA, Bayer, Roche, Receptos, Genzyme

    Editorial Boards:

    1. Journal of Neuroimmunology - member of editorial board - 1994 now.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1)Genzyme 2) Novartis 3) BiogenIdec 4) Roche 5)Synthon 6)Merck Serono 7) Ono 8) Teva

    Speakers' Bureaus:

    1. 1) Novartis 2) Merck-Serono 3) BiogenIdec 4) Bayer 5)Genzyme

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. Research grant from National Research Center (Poland)and fro National Center for Research and Development.

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Ih Chang, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Biogen Senior Director, Biostatistics 2014-present

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. As Biogen employee.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. As Biogen employee.

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Mark Novas, MD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Biogen employeee

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. Biogen

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Jitesh Rana, MD and
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. 1) Biogen, Global Medical Director 2008 - 2015 2) Senior Medical Director 2015 3) Global Medical Director 2015 - current

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. Biogen

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Jing L. Marantz, MD, PhD
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Biogen, Senior Director, Medical Affairs, 2014-current

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. Biogen

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

    1. Mellen Center for Multiple Sclerosis Treatment and Research (RJF), Cleveland Clinic, Cleveland, OH; St. Josef Hospital (AC, RG), Ruhr University, Bochum, Germany; Multiple Sclerosis Program (JTP), Baylor Institute for Immunology Research, Dallas, TX; Medical University of Lodz (KS), Lodz, Poland; and Biogen (IC, MN, JR, JLM), Cambridge, MA. Dr. Novas is currently with Alexion Pharmaceuticals, Chesire, CT; and Dr. Rana is currently with Sanofi-Genzyme, Cambridge, MA.
    1. Correspondence to:
      FOXR{at}ccf.org
    View Full Text

    Article usage

    Article usage: April 2016 to February 2023

    AbstractFullPdfSource
    Apr 20163911114Highwire
    May 2016192074Highwire
    Jun 201671832165Highwire
    Jun 2016021pmc
    Jul 20166391698Highwire
    Jul 2016012275pmc
    Aug 20162531169Highwire
    Aug 201609238pmc
    Sep 20161421059Highwire
    Sep 201609825pmc
    Oct 2016130772Highwire
    Oct 2016010647pmc
    Nov 2016128767Highwire
    Nov 2016010831pmc
    Dec 201685849Highwire
    Dec 201606628pmc
    Jan 2017104557Highwire
    Jan 201708233pmc
    Feb 201780469Highwire
    Feb 2017010228pmc
    Mar 201770951Highwire
    Mar 201709928pmc
    Apr 201749646Highwire
    Apr 2017326877pmc
    May 201771956Highwire
    May 20173784107pmc
    Jun 201744149Highwire
    Jun 20171971107pmc
    Jul 201739634Highwire
    Jul 2017215177pmc
    Aug 201742163Highwire
    Aug 2017176695pmc
    Sep 201733761Highwire
    Sep 2017186280pmc
    Oct 20175513101Highwire
    Oct 20171779100pmc
    Nov 2017321346Highwire
    Nov 20172498120pmc
    Dec 2017101272Highwire
    Jan 2018171742Highwire
    Feb 201891944Highwire
    Mar 2018133746Highwire
    Apr 201892361Highwire
    Apr 20181897123pmc
    May 2018103755Highwire
    Jun 2018947111Highwire
    Jun 201813115140pmc
    Jul 2018655106Highwire
    Aug 201823050Highwire
    Aug 201823114139pmc
    Sep 201865249Highwire
    Oct 2018104648Highwire
    Nov 201874256Highwire
    Dec 2018943746Highwire
    Jan 20192135351Highwire
    Feb 20192427280Highwire
    Mar 20191816662Highwire
    Apr 20191115242Highwire
    May 20192012842Highwire
    Jun 20191510043Highwire
    Jul 20191216725Highwire
    Aug 2019727133Highwire
    Sep 2019623836Highwire
    Oct 20191229232Highwire
    Nov 20191620336Highwire
    Dec 20192915935Highwire
    Jan 2020266321Highwire
    Feb 202065932Highwire
    Mar 202065747Highwire
    Apr 2020123428Highwire
    May 20201311651Highwire
    Jun 20201511632Highwire
    Jul 20204123425Highwire
    Aug 202013316Highwire
    Sep 202086424Highwire
    Oct 202066220Highwire
    Nov 20201737745Highwire
    Dec 20201085030Highwire
    Jan 20211215628Highwire
    Feb 202177422Highwire
    Mar 202158026Highwire
    Apr 202155723Highwire
    May 2021515815Highwire
    Jun 20211313715Highwire
    Jul 202194018Highwire
    Aug 2021128221Highwire
    Sep 202155114Highwire
    Oct 202186126Highwire
    Nov 202153425Highwire
    Dec 202111358Highwire
    Jan 202210363Highwire
    Feb 202255919Highwire
    Mar 202275515Highwire
    Apr 202233813Highwire
    May 202263220Highwire
    Jun 20224386Highwire
    Jul 2022315312Highwire
    Aug 2022112343Highwire
    Sep 20221216315Highwire
    Oct 202286014Highwire
    Nov 20221113420Highwire
    Dec 202273913Highwire
    Jan 2023107720Highwire
    Feb 2023103719Highwire

    The Nerve!: Rapid online correspondence

    No comments have been published for this article.
    Comment

    REQUIREMENTS

    If you are uploading a letter concerning an article:
    You must have updated your disclosures within six months: http://submit.neurology.org

    Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

    If you are responding to a comment that was written about an article you originally authored:
    You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
    and apply to letter.

    Submission specifications:

    • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
    • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
    • Submit only on articles published within 6 months of issue date.
    • Do not be redundant. Read any comments already posted on the article prior to submission.
    • Submitted comments are subject to editing and editor review prior to posting.

    More guidelines and information on Disputes & Debates

    Compose Comment

    More information about text formats

    Plain text

    • No HTML tags allowed.
    • Web page addresses and e-mail addresses turn into links automatically.
    • Lines and paragraphs break automatically.
    Author Information
    NOTE: The first author must also be the corresponding author of the comment.
    First or given name, e.g. 'Peter'.
    Your last, or family, name, e.g. 'MacMoody'.
    Your email address, e.g. higgs-boson@gmail.com
    Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
    Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
    Publishing Agreement
    NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

    Vertical Tabs

    You May Also be Interested in

    Back to top
    Advertisement

    Topics Discussed

    Alert Me

    Recommended articles